Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
Tali Cukierman-Yaffe; Hertzel C Gerstein; Jan Basile; M Angelyn Bethel; Ernesto G Cardona-Muñoz; Ignacio Conget; Gilles Dagenais; Edward Franek; Stephanie Hall; Nicolae Hancu; Petr Jansky; Mark Lakshmanan; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Valdis Pirags; Nana Pogosova; Jeffrey Probstfield; Purnima Rao-Melacini; Chinthanie Ramasundarahettige; Peter J Raubenheimer; Matthew C Riddle; Lars Rydén; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Abstract
Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown.Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed.Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors.Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.
Journal | THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM |
ISSN | 1945-7197 |
Published | 14 Jul 2022 |
Volume | 107 |
Issue | 8 |
Pages | e3448 e3454 e3448-e3454 |
DOI | 10.1210/clinem/dgac200 |
Type | Clinical Trial | Journal Article | Research Support, Non-U.S. Gov't |
Sponsorship | NHMRC: 1173952 |